# Brickell Price to Earning

BBI | Stock | ## USD 3.36 0.09 2.75% |

Brickell Biotech fundamentals help investors to digest information that contributes to Brickell Biotech's financial success or failures. It also enables traders to predict the movement of Brickell Stock. The fundamental analysis module provides a way to measure Brickell Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Brickell Biotech stock.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Brickell | Price to Earning |

**M**).

## Brickell Price to Earning Analysis

Brickell Biotech's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit. 2019 | 2020 | 2021 | 2022 (projected) | |

Revenues USD | 7.92 M | 1.82 M | 404 K | 414.63 K |

Revenues | 7.92 M | 1.82 M | 404 K | 414.63 K |

P/E | = | Market Value Per Share Earnings Per Share |

## Current Brickell Biotech Price to Earning | (35.16) X |

Most of Brickell Biotech's fundamental indicators, such as Price to Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brickell Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Compare to competition |

Based on the latest financial disclosure, the price to earning indicator of Brickell Biotech is roughly -35.1557 times. This is 236.05% lower than that of the sector and notably lower than that of the Price to Earning industry. The price to earning for all United States stocks is notably higher than that of the company.

## Brickell Biotech Current Valuation Drivers

We derive many important indicators used in calculating different scores of Brickell Biotech from analyzing Brickell Biotech's financial statements. These drivers represent accounts that assess Brickell Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Brickell Biotech's important valuation drivers and their relationship over time.

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Net Income Per Employee | (122.58 K) | (175.13 K) | (541.8 K) | (1.59 M) | (1.83 M) | (1.88 M) | |

Revenue Per Employee | 198.51 K | 186.74 K | 54.07 K | 527.8 K | 475.02 K | 512.52 K | |

Average Assets | 58.08 M | 45.63 M | 34.66 M | 25.13 M | 30.46 M | 39.21 M | |

Earnings Before Interest Taxes and Depreciation Amortization EBITDA | (12.17 M) | (8.1 M) | (21.75 M) | (20.9 M) | (39.38 M) | (40.42 M) | |

Earnings Before Interest Taxes and Depreciation Amortization USD | (12.17 M) | (8.1 M) | (21.75 M) | (20.9 M) | (39.38 M) | (40.42 M) | |

Earnings before Tax | (12.96 M) | (9.24 M) | (23.88 M) | (20.91 M) | (39.47 M) | (40.51 M) | |

Average Equity | 45.92 M | 23.07 M | 27.82 M | 17.91 M | 24.09 M | 32.33 M | |

Enterprise Value | 12.67 M | 13.45 M | 4.59 M | 22.04 M | 4.97 M | 5.1 M | |

Free Cash Flow | (8.68 M) | 3.96 M | (35.99 M) | (20.06 M) | (36.18 M) | (37.14 M) | |

Invested Capital | 37.84 M | (15.21 M) | 488 K | (2.4 M) | (1.98 M) | (2.03 M) | |

Invested Capital Average | 32.37 M | 28.85 M | 20.09 M | (1.32 M) | (2.55 M) | (2.62 M) | |

Market Capitalization | 23.07 M | 25.74 M | 11.72 M | 41.77 M | 26.33 M | 27.03 M | |

Tangible Asset Value | 79.79 M | 8.31 M | 18.14 M | 33.63 M | 29.72 M | 36.69 M | |

Working Capital | 59.4 M | (11.82 M) | 7.47 M | 27.18 M | 24.79 M | 28.97 M |

## Brickell Fundamentals

Return On Equity | (176.49) % | |||

Return On Asset | (85.20) % | |||

Current Valuation | (9.36 M) | |||

Shares Outstanding | 115.05 M | |||

Shares Owned by Insiders | 1.31 % | |||

Shares Owned by Institutions | 15.95 % | |||

Number of Shares Shorted | 181.26 K | |||

Price to Earning | (35.16) X | |||

Price to Book | 17.62 X | |||

Price to Sales | 952.21 X | |||

Revenue | 479 K | |||

Gross Profit | (27.83 M) | |||

EBITDA | (40.62 M) | |||

Net Income | (39.88 M) | |||

Cash and Equivalents | 17.29 M | |||

Cash per Share | 6.52 X | |||

Total Debt | 53 K | |||

Debt to Equity | 0.003 % | |||

Current Ratio | 4.36 X | |||

Book Value Per Share | 0.22 X | |||

Cash Flow from Operations | (39.8 M) | |||

Short Ratio | 0.43 X | |||

Earnings Per Share | (0.62) X | |||

Number of Employees | 16 | |||

Beta | 0.41 | |||

Market Capitalization | 456.11 M | |||

Total Asset | 59.37 M | |||

Retained Earnings | (91.69 M) | |||

Working Capital | 47.05 M | |||

Current Asset | 52.66 M | |||

Current Liabilities | 5.61 M |

## About Brickell Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Brickell Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brickell Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brickell Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Last Reported | Projected for 2022 | |

Price to Earnings Ratio | (0.47) | (0.50) |

Earnings Before Interest Taxes and Depreciation Amortization EBITDA | -39.4 M | -40.4 M |

Earnings before Tax | -39.5 M | -40.5 M |

## Brickell Biotech Investors Sentiment

The influence of Brickell Biotech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Brickell. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Investor biases related to Brickell Biotech's public news can be used to forecast risks associated with investment in Brickell. The trend in average sentiment can be used to explain how an investor holding Brickell can time the market purely based on public headlines and social activities around Brickell Biotech. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.

Brickell Biotech's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Brickell Biotech's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Brickell Biotech's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Brickell Biotech.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Brickell Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Brickell Biotech's short interest history, or implied volatility extrapolated from Brickell Biotech options trading.

## Pair Trading with Brickell Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brickell Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brickell Biotech will appreciate offsetting losses from the drop in the long position's value.### Moving together with Brickell Biotech

0.87 | ABVC | Abvc Biopharma | Earnings Call Tomorrow | PairCorr | |||

0.69 | AGTC | Applied Genetic Tech | Fiscal Year End 22nd of September 2022 | PairCorr |

### Moving against Brickell Biotech

0.91 | AGL | Agilon Health | Downward Rally | PairCorr | |||

0.79 | ARWR | Arrowhead Pharma | Fiscal Year End 28th of November 2022 | PairCorr | |||

0.6 | ALXO | Alx Oncology Holdings | Aggressive Push | PairCorr |

The ability to find closely correlated positions to Brickell Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brickell Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brickell Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brickell Biotech to buy it.

The correlation of Brickell Biotech is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brickell Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brickell Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Brickell Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Continue to Brickell Biotech Piotroski F Score and Brickell Biotech Altman Z Score analysis. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Piotroski F Score module to get Piotroski F Score based on binary analysis strategy of nine different fundamentals.

## Complementary Tools for Brickell Stock analysis

When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.

Cryptocurrency CenterBuild and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | Go | |

Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk | Go | |

Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments | Go | |

Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. | Go | |

Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account | Go | |

Commodity Channel IndexUse Commodity Channel Index to analyze current equity momentum | Go | |

Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios | Go | |

Bollinger BandsUse Bollinger Bands indicator to analyze target price for a given investing horizon | Go | |

Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios | Go | |

My Watchlist AnalysisAnalyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | Go | |

Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | Go | |

Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios | Go |

Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Market Capitalization 8.9 M | Quarterly Revenue Growth YOY 27.58 | Return On Assets -0.85 | Return On Equity -1.76 |

The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.